<DOC>
	<DOC>NCT01395602</DOC>
	<brief_summary>The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.</brief_summary>
	<brief_title>Effect of Cabergoline on Weight and Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>age 18 55 years BMI 30 40 diabetes, clinically significant medical condition, use of medications that effect blood glucose or body weight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>